Upregulation of LAG-3, TIM-3, TIGIT, and VISTA has been observed in patients with tumor recurrence after anti-PD-1/L1 or anti-CTLA-4 therapy, indicating the presence of an underlying mechanism of acquired resistance [342]. This evidence concerns the gene PDCD1 and neoplasm.